A Clinical Study of TQB3824 in Subjects With Advanced Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
TQB3824 blocks function of a specific protein called Cell Division Cycle 7 (CDC7) kinase in
the human body, which plays important roles in the maintenance of DNA replication forks and
DNA damage response pathways. This study will evaluate the safety, tolerability and
pharmacokinetics of TQB3824.